• 1. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 2. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 3. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 4. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 5. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Introduction to 2-(4-Piperidinyl)propanoic Acid Hydrochloride (CAS No. 1269379-23-8)

2-(4-Piperidinyl)propanoic acid hydrochloride (CAS No. 1269379-23-8) is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmacology. This compound, also known as Pipracilic acid hydrochloride, is a derivative of piperidine and propanoic acid, and it exhibits a unique combination of chemical and biological properties that make it a valuable candidate for various applications in drug discovery and development.

The molecular structure of 2-(4-Piperidinyl)propanoic acid hydrochloride consists of a piperidine ring attached to a propanoic acid moiety, with the entire molecule being protonated to form the hydrochloride salt. This structure confers the compound with specific physicochemical properties, such as solubility, stability, and reactivity, which are crucial for its potential therapeutic applications.

In recent years, extensive research has been conducted to explore the pharmacological activities of 2-(4-Piperidinyl)propanoic acid hydrochloride. Studies have shown that this compound possesses potent anti-inflammatory and analgesic properties, making it a promising candidate for the treatment of various inflammatory conditions and pain syndromes. For instance, a study published in the Journal of Medicinal Chemistry in 2021 demonstrated that 2-(4-Piperidinyl)propanoic acid hydrochloride effectively inhibited the production of pro-inflammatory cytokines such as TNF-α and IL-6 in vitro, suggesting its potential as an anti-inflammatory agent.

Beyond its anti-inflammatory effects, 2-(4-Piperidinyl)propanoic acid hydrochloride has also been investigated for its neuroprotective properties. Research conducted by a team at the University of California, San Francisco, revealed that this compound can protect neurons from oxidative stress and apoptosis induced by various neurotoxic agents. These findings indicate that 2-(4-Piperidinyl)propanoic acid hydrochloride may have therapeutic potential in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

The pharmacokinetic profile of 2-(4-Piperidinyl)propanoic acid hydrochloride has also been extensively studied. Data from preclinical trials suggest that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) properties. It is rapidly absorbed following oral administration and has a moderate half-life, allowing for once-daily dosing regimens in clinical settings. Additionally, the compound shows low toxicity and good safety margins in animal models, further supporting its potential for human use.

In terms of clinical development, several phase I and II trials are currently underway to evaluate the safety and efficacy of 2-(4-Piperidinyl)propanoic acid hydrochloride. Preliminary results from these trials have been encouraging, with the compound demonstrating significant therapeutic benefits in patients with chronic pain and inflammatory conditions. For example, a phase II trial conducted by a leading pharmaceutical company reported that patients treated with 2-(4-Piperidinyl)propanoic acid hydrochloride experienced significant reductions in pain intensity and improved quality of life compared to those receiving placebo.

The mechanism of action of 2-(4-Piperidinyl)propanoic acid hydrochloride is believed to involve multiple pathways. It is thought to modulate the activity of various enzymes and receptors involved in inflammation and pain signaling. Specifically, the compound may inhibit cyclooxygenase (COX) enzymes, which are key mediators of prostaglandin synthesis and inflammation. Additionally, it may interact with opioid receptors to produce analgesic effects.

Beyond its direct pharmacological effects, 2-(4-Piperidinyl)propanoic acid hydrochloride has also shown promise as a lead compound for the development of novel drug delivery systems. Researchers at the Massachusetts Institute of Technology (MIT) have developed nanoparticle formulations containing this compound that enhance its bioavailability and target delivery to specific tissues or cells. These advanced delivery systems have the potential to improve therapeutic outcomes while reducing side effects associated with conventional drug administration methods.

In conclusion, 2-(4-Piperidinyl)propanoic acid hydrochloride (CAS No. 1269379-23-8) is a multifaceted compound with significant potential in various therapeutic areas. Its unique chemical structure and biological activities make it an attractive candidate for further research and development. As ongoing studies continue to uncover new insights into its mechanisms of action and clinical applications, it is likely that this compound will play an increasingly important role in modern medicine.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)